|1.||Michod, David: 2 articles (07/2007 - 05/2007)|
|2.||Widmann, Christian: 2 articles (07/2007 - 05/2007)|
|3.||Barras, D: 1 article (10/2014)|
|4.||Widmann, C: 1 article (10/2014)|
|5.||Lorusso, G: 1 article (10/2014)|
|6.||Rüegg, C: 1 article (10/2014)|
|7.||Xu, Jing: 1 article (12/2012)|
|8.||Wei, Qichun: 1 article (12/2012)|
|9.||Krueger, Thorsten: 1 article (07/2007)|
|10.||Cheng, Cai: 1 article (07/2007)|
12/01/2012 - "TAT-RasGAP(317-326) is demonstrated to potentiate the efficacy of γ-irradiation-mediated cell killing both in tumor cell lines and in mouse tumor models, disregarding the status of p53, but not in non-cancer cells. "
10/30/2014 - "These results show that TAT-RasGAP(317-326), besides its ability to favor tumor cell death, hampers cell migration and invasion."
10/30/2014 - "In contrast, deleted in liver cancer-1, a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found to be required for TAT-RasGAP(317-326) to promote cell adherence and inhibit migration. "
10/30/2014 - "TAT-RasGAP(317-326), a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled with a cell-permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer treatments. "
05/01/2007 - "These results indicate that TAT-RasGAP(317-326) sensitizes tumor cells by activating signals that intersect with the p53 pathway downstream of, or at the level of, proapoptotic p53 target gene products to increase the activation of the mitochondrial death pathway."